91895-29-3

Basic information

• Product Name: 6,7-difluoroquinoxaline-2,3(1H,4H)-dione
• Synonyms: 6,7-difluoroquinoxaline-2,3(1H,4H)-dione;6,7-Difluoro-1,4-dihydroquinoxaline-2,3-dione;2,3-Quinoxalinedione, 6,7-difluoro-1,4-dihydro-
• CAS NO: 91895-29-3
• Molecular Formula: C₈H₄F₂N₂O₂
• Molecular Weight: 198.1263664
• Mol File: 91895-29-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6,7-difluoroquinoxaline-2,3(1H,4H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-difluoroquinoxaline-2,3(1H,4H)-dione(91895-29-3)
• EPA Substance Registry System: 6,7-difluoroquinoxaline-2,3(1H,4H)-dione(91895-29-3)

Safety Data

• Hazardous Substances Data: 91895-29-3(Hazardous Substances Data)

Usage

General Description

6,7-difluoroquinoxaline-2,3(1H,4H)-dione is a chemical compound that belongs to the quinoxaline family. It is a heterocyclic compound containing two nitrogen and two carbon atoms in a six-membered ring structure. 6,7-difluoroquinoxaline-2,3(1H,4H)-dione is known for its potential biological activities, such as antimicrobial, antimalarial, and anti-tumor properties. It is also used in the synthesis of various pharmaceuticals and agrochemicals. The presence of fluorine atoms in its structure enhances its chemical and biological properties, making it a valuable compound in medicinal chemistry research and drug development. Overall, 6,7-difluoroquinoxaline-2,3(1H,4H)-dione has potential applications in pharmaceuticals, agrochemicals, and biological studies due to its unique chemical structure and properties.

Upstream product

• 144-62-7 oxalic acid 
• 76179-40-3 2-amino-4,5-difluoroaniline 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 91895-30-6 2,3-dichloro-6,7-difluoroquinoxaline 

Relevant articles and documents

Synthesis of novel halogenated heterocycles based on o‐phenylenediamine and their interactions with the catalytic subunit of protein kinase ck2

Protein kinase CK2 is a highly pleiotropic protein kinase capable of phosphorylating hundreds of protein substrates. It is involved in numerous cellular functions, including cell viability, apoptosis, cell proliferation and survival, angiogenesis, or ER‐stress response. As CK2 activity is found perturbed in many pathological states, including cancers, it becomes an attractive target for the pharma. A large number of low‐mass ATP‐competitive inhibitors have already been developed, the majority of them halogenated. We tested the binding of six series of halogenated heterocyclic ligands derived from the commercially available 4,5‐dihalo‐benzene‐1,2‐diamines. These ligand series were selected to enable the separation of the scaffold effect from the hydrophobic interactions attributed directly to the presence of halogen atoms. In silico molecular docking was initially applied to test the capability of each ligand for binding at the ATP‐binding site of CK2. HPLC‐derived ligand hydrophobicity data are compared with the binding affinity assessed by low‐volume differential scanning fluorimetry (nanoDSF). We identified three promising ligand scaffolds, two of which have not yet been described as CK2 inhibitors but may lead to potent CK2 kinase inhibitors. The inhibitory activity against CK2α and toxicity against four reference cell lines have been determined for eight compounds identified as the most promising in nanoDSF assay.

Imidazo[1,2-a]quinoxalin-4-amines: A novel class of nonxanthine A1- adenosine receptor antagonists

The syntheses and A1 adenosine receptor affinities of a number of imidazo[1,2-a]quinoxalin-4-amines are reported. Structure-activity relationships within the series and in comparison with other similar tricyclic nonxanthine adenosine antagonists are discussed, leading to a putative common binding mode of these nitrogen-containing heterocycles to A1 adenosine receptors. Secondary amino compounds displayed the best affinities toward A1 receptors, while the tertiary amines were almost devoid of activity, thus suggesting a crucial role for the hydrogen bond-forming 4-NH group. Remarkably higher potencies for 1-methyl and N-cyclopentyl derivatives were also found. 4-Cyclopentylamino-1-methylimidazo[1,2-a]quinoxaline (IRFI 165) is the most potent compound in this series, having K(i)(A1) = 7.9 nM. It is also provided with a good A1 selectivity both versus A(2a) and A3 subtypes and was selected for further pharmacological studies.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.